ID   SMS-KAN
AC   CVCL_7131
SY   sms-KAN
DR   CGH-DB; 9096-4
DR   Cosmic; 717425
DR   Cosmic; 848932
DR   Cosmic; 922671
DR   Cosmic; 923826
DR   Cosmic; 930079
DR   Cosmic; 1019938
DR   Cosmic; 1526650
DR   GEO; GSM2371260
DR   GEO; GSM2394371
DR   IARC_TP53; 23596
DR   Wikidata; Q54954986
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-008304-6.50015-4;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=3456456;
RX   PubMed=7037175;
RX   PubMed=8665486;
RX   PubMed=12702577;
RX   PubMed=15390183;
RX   PubMed=15720811;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=24792489;
RX   PubMed=28350380;
WW   http://www.cccells.org/dl/NB_Data_Sheets/SMS-KAN_Cell_Line_Data_Sheet_COGcell_org.pdf
CC   Characteristics: Neuroblastic type (N-type) (PubMed=15720811).
CC   Doubling time: ~95 hours (PubMed=3456456).
CC   Omics: Array-based CGH.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): COG
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,11
ST   D16S539: 11,13
ST   D18S51: 17,21
ST   D19S433: 12
ST   D21S11: 28,30
ST   D2S1338: 18,19
ST   D3S1358: 15,17
ST   D5S818: 9,13
ST   D7S820: 8,9
ST   D8S1179: 14,16
ST   FGA: 19,21
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7132 ! SMS-KANR
SX   Female
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 21
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999).
//
RX   DOI=10.1016/B978-0-12-008304-6.50015-4;
RA   Biedler J.L., Meyers M.B., Spengler B.A.;
RT   "Homogeneously staining regions and double minute chromosomes,
RT   prevalent cytogenetic abnormalities of human neuroblastoma cells.";
RL   (In book chapter) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York; USA (1983).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994).
//
RX   PubMed=3456456; DOI=10.1093/jnci/76.3.375;
RA   Reynolds C.P., Biedler J.L., Spengler B.A., Reynolds D.A., Ross R.A.,
RA   Frenkel E.P., Smith R.G.;
RT   "Characterization of human neuroblastoma cell lines established before
RT   and after therapy.";
RL   J. Natl. Cancer Inst. 76:375-387(1986).
//
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
//
RX   PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4;
RA   Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.;
RT   "The p16 and p18 tumor suppressor genes in neuroblastoma: implications
RT   for drug resistance.";
RL   Cancer Lett. 104:183-192(1996).
//
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
//
RX   PubMed=15390183; DOI=10.1002/gcc.20096;
RA   Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.;
RT   "Expression profiles and clinical relationships of ID2, CDKN1B, and
RT   CDKN2A in primary neuroblastoma.";
RL   Genes Chromosomes Cancer 41:297-308(2004).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310; PMCID=PMC1531688;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K.A., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33; PMCID=PMC5369315;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//